Epitalon Compounding Pharmacy: How to Read a Certificate of Analysis

What a Certificate of Analysis Can and Cannot Tell You

A certificate of analysis describes testing done on one lot of material. FDA's page on bulk substances for state-licensed pharmacies and physicians says a bulk drug substance must be accompanied by a valid certificate of analysis and must have been manufactured by an establishment registered with FDA [2]. The requirement concerns the quality documentation for the substance. It says nothing about whether the peptide works or is safe.

Epitalon is also sold online as 'research use only' vials, capsules and oral sprays [1]. A certificate that comes with such a product is not the same as one supplied to meet the compounding requirement above.

Identity: The Line Worth Checking First

Epitalon is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, with a molecular weight of about 390 g/mol as the free base and about 450 g/mol as the acetate [1]. The name and the form on the certificate can be compared with those values.

Watch the name as well. FDA treats epitalon and epithalamin, a polypeptide extract of animal pineal gland, as different substances [1]. A 2015 analysis identified epitalon in two illegal pharmaceutical preparations sold for cancer, old age and retinitis pigmentosa [1][3].

Purity: What a Percentage Can and Cannot Mean

FDA found no listing for epitalon in the European or Japanese pharmacopeias either [1]. A purity figure on an epitalon certificate therefore has no compendial epitalon standard to be compared with.

For injectable peptides in general, FDA's stated concern is immunogenicity risk from aggregation and peptide-related impurities. For epitalon specifically, FDA said it has not identified safety-related information for the proposed route of administration [4]. In its July 2026 evaluation, FDA also found no pharmacokinetic data and no clinical study assessing epitalon's safety [1].

Does a Certificate Make Compounded Epitalon Legal?

No. Epitalon is not on FDA's lists of bulk substances for state-licensed compounders or for outsourcing facilities, and FDA's policy of generally not acting against compounders (category 1) does not cover it [4][5][6][2]. FDA's Pharmacy Compounding Advisory Committee voted on July 24, 2026 in favor of adding it to the bulks list, against FDA staff's recommendation. The vote is advice only, and listing requires formal rulemaking [7][8].

HHS's draft enforcement-discretion policy, filed in October 2026, names epitalon among six peptides. Its conditions include an FDA-registered manufacturer with a certificate of analysis. The notice states that it establishes no rights and is not binding on HHS or the public [8][9].

FDA found no pharmacy that compounds epitalon and no outsourcing facility reporting it. The US Attorney's office reported that a Kentucky pharmacy compounded and distributed epitalon products from October 25, 2018 to April 1, 2020 [1].

What the Certificate Cannot Tell You

• The telomerase and telomere finding came from cultured human fetal fibroblasts, not from people [10].
• FDA warned that telomerase activation and telomere lengthening carry a mechanistic potential to be carcinogenic, and that the mouse studies of cancer and chromosome damage were too limited to show safety [1].
• A 2026 narrative review concluded epitalon is biologically active but clinically unproven [11].
• There is no approved dose. Websites FDA reviewed suggest 5 mg to 10 mg a day by injection or orally in cycles, which is marketing rather than evidence [1].